TY - JOUR
T1 - Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting
AU - Criscitiello, Carmen
AU - Viale, Giulia
AU - Curigliano, Giuseppe
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Purpose of review: A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway. Recent findings: Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer. Summary: Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.
AB - Purpose of review: A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway. Recent findings: Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer. Summary: Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.
KW - adjuvant
KW - breast cancer
KW - CDK 4/6 inhibitors
KW - neoadjuvant
UR - http://www.scopus.com/inward/record.url?scp=85031311647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031311647&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000401
DO - 10.1097/CCO.0000000000000401
M3 - Review article
C2 - 28872469
AN - SCOPUS:85031311647
VL - 29
SP - 428
EP - 433
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
SN - 1040-8746
IS - 6
ER -